A total of 17 McMaster University research projects, including two led by PHRI scientists, are among the recipients of the Canadian federal government’s most recent COVID-19 rapid research response grants, announced today.
John Eikelboom, Senior Scientist, PHRI, is receiving $2,937,119 from the Canadian Institutes for Health Research (CIHR) for Anti-Coronavirus Therapy (ACT) to prevent COVID-19 disease progression: a clinical trial platform, to rapidly evaluate whether several commonly available interventions can be repurposed for treating COVID-19, specifically to determine whether treatments that a) reduce the levels of virus in the body, b) reduce the response by the body to the infection (i.e., inflammation), and c) prevent blood clotting can prevent COVID-19 disease progression.
Darryl Leong, Scientist, PHRI, is receiving $2,066,870 from the International Development Research Centre (IDRC) for PURE SARS-CoV-2, a sub-study of PHRI’s flagship study, Prospective Urban Rural Epidemiology (PURE).
The PURE SARS-CoV-2 sub-study is looking at:
- Factors that increase the risk of people getting infected by COVID-19 or that protect against infection
- The long-term health effects of getting infected by COVID-19. Specifically, the study team wants to know whether having had COVID-19 infection – even if symptoms were not severe – can lead to long-term lung damage and other complications, like pneumonia, heart attacks, heart failure, stroke.
More details on all 17 of the McMaster University award recipients at “McMaster scoops up $20M more for COVID-19 research.”